AGM, page-25

Simonig, I like the way you're thinking and hope that GK and staff quit trying to swim uphill in the US. Europe is an unknown and while there is a chance of success, it could easily evolve into another "punching tarbaby" situation.
Do the next trial in Australia, show some efficacy, and (assuming some level of success) begin allowing treatment in Australia.
Medical travel is becoming increasingly common and tracking future treatment groups could further serve to reinforce the safety and efficacy of PBT2 in treating HD. If you want to eventually create serious pressure on the FDA, just show treatment success elsewhere with some consistency. There are estimated to be approx. 30k folks with HD in the US. They'll start screaming, "Why to HE** do we have to travel to Australia to get treatment?"

Perhaps other trials (both confronting different neurological insults and other PRAN drugs) should be carried out in AUS. Beside encouraging "medical tourism" it would certainly impart some prestige as well.

If PRAN gets it right this could be a big win-win.